Medacta Group SA (MOVE) - Total Assets
Based on the latest financial reports, Medacta Group SA (MOVE) holds total assets worth CHF860.76 Million CHF (≈ $1.09 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Medacta Group SA service its debt to assess how comfortably operating cash covers total debt obligations.
Medacta Group SA - Total Assets Trend (2015–2024)
This chart illustrates how Medacta Group SA's total assets have evolved over time, based on quarterly financial data. See Medacta Group SA shareholders equity for net asset value and shareholders' equity analysis.
Medacta Group SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Medacta Group SA's total assets of CHF860.76 Million consist of 49.9% current assets and 50.1% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 4.0% |
| Accounts Receivable | CHF108.54 Million | 13.7% |
| Inventory | CHF234.41 Million | 29.6% |
| Property, Plant & Equipment | CHF317.50 Million | 40.1% |
| Intangible Assets | CHF53.57 Million | 6.8% |
| Goodwill | CHF59.00K | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Medacta Group SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see MOVE stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medacta Group SA's current assets represent 49.9% of total assets in 2024, an increase from 47.1% in 2015.
- Cash Position: Cash and equivalents constituted 4.0% of total assets in 2024, up from 3.3% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 3.0% in 2015.
- Asset Diversification: The largest asset category is property, plant & equipment at 40.1% of total assets.
Medacta Group SA Competitors by Total Assets
Key competitors of Medacta Group SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Edwards Lifesciences Corp
NYSE:EW
|
USA | $13.32 Billion |
|
DexCom Inc
NASDAQ:DXCM
|
USA | $6.63 Billion |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
|
China | CN¥805.10 Million |
|
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212
|
China | CN¥1.86 Billion |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Corentec Co Ltd
KQ:104540
|
Korea | ₩175.16 Billion |
|
Adherium Ltd
AU:ADR
|
Australia | AU$4.16 Million |
Medacta Group SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.39 | 2.20 | 1.71 |
| Quick Ratio | 0.95 | 0.84 | 0.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CHF257.60 Million | CHF198.53 Million | CHF79.77 Million |
Medacta Group SA - Advanced Valuation Insights
This section examines the relationship between Medacta Group SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.16 |
| Latest Market Cap to Assets Ratio | 3.87 |
| Asset Growth Rate (YoY) | 13.8% |
| Total Assets | CHF792.18 Million |
| Market Capitalization | $3.06 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Medacta Group SA's assets at a significant premium (3.87x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Medacta Group SA's assets grew by 13.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Medacta Group SA (2015–2024)
The table below shows the annual total assets of Medacta Group SA from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CHF792.18 Million ≈ $1.00 Billion |
+13.84% |
| 2023-12-31 | CHF695.87 Million ≈ $879.77 Million |
+19.06% |
| 2022-12-31 | CHF584.49 Million ≈ $738.95 Million |
+19.46% |
| 2021-12-31 | CHF489.27 Million ≈ $618.56 Million |
+10.71% |
| 2020-12-31 | CHF441.94 Million ≈ $558.73 Million |
+7.12% |
| 2019-12-31 | CHF412.56 Million ≈ $521.59 Million |
+12.85% |
| 2018-12-31 | CHF365.60 Million ≈ $462.21 Million |
+21.94% |
| 2017-12-31 | CHF299.81 Million ≈ $379.04 Million |
+11.17% |
| 2016-12-31 | CHF269.68 Million ≈ $340.95 Million |
+23.23% |
| 2015-12-31 | CHF218.84 Million ≈ $276.67 Million |
-- |
About Medacta Group SA
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Latin America, North America, the Asia-Pacific, and Middle East and Africa. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine surgery. Medacta Group SA was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.